Rheumatoid Arthritis Market Research
What is Rheumatoid Arthritis (RA)?
Rheumatoid arthritis (RA) is an autoimmune disorder affecting the joints, causing swelling and inflammation. With RA, the body begins to attack its own healthy tissue, causing damage to the lining of the joints. RA may first begin to attack smaller joints in the fingers and toes, though it can affect other areas of the body such as the shoulders, knees, ankles, and hips. Left untreated, RA can deform the joints and erode the bone. Symptoms of RA include: joint swelling, joint pain, tenderness, stiffness, fever, and fatigue. RA may also impact other parts of the body, including eyes, kidneys, blood vessels, nerve tissue, and more. RA symptoms typically present themselves through flare ups (periods in which the pain gets worse). While there is no cure for RA, there are various treatments on the market such as Humira (adalimumab), Rinvoq (upadacitinib), Olumiant (baricitinib), Enbrel (etanercept), Riabni (rituximab), Avsola (infliximab), Amjevita (adalimumab), Orencia (abatacept), Remicade (infliximab), Unbranded infliximab, Simponi (golimumab), Truxima (rituximab), Cimzia (certolizumab), Actemra (tocilizumab), Rituxan (rituximab), Kevzara (sarilumab), Renflexis (infliximab), Xeljanz (tofacitinib), Ruxience (rituximab) and Inflectra (infliximab).
Spherix Global Insights – Rheumatology – Rheumatoid Arthritis
Spherix Global Insights’ rheumatology therapeutic team is a leading provider of independent syndicated rheumatoid arthritis market research, insights, business intelligence & advisory services.
Spherix’s rheumatology team publishes four (4) studies in RA including:
- RealTime Dynamix™: Rheumatoid Arthritis (US)
- RealTime Dynamix™: Rheumatoid Arthritis (EU5)
- Launch Dynamix™: Artlegia (R-Pharm) in Rheumatoid Arthritis (US)*
- Patient Chart Dynamix™: Biologic/Small Molecule Switching in Rheumatoid Arthritis (US)
*Pending approvals and launch
Spherix’s RealTime Dynamix™ service includes quarterly or semiannual reports, respectively in the US and EU, providing an unbiased view of the competitive landscape within the RA market.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide monthly benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports covering promotional activity, barriers to uptake, and patient types being identified for the launch brand.
Spherix’s Patient Chart Dynamix™ service includes patient level data detailing clinical and non-clinical patient demographics, along with rationale for treatment choices. It reveals real patient management patterns through rigorous analysis of large-scale patient chart audits.
Follow Spherix Rheumatology on Social Media
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: